■系统评估高压氧疗法(HBOT)作为帕金森病(PD)患者睡眠障碍的辅助疗法的疗效。
■从成立到2023年9月,我们在八个数据库中进行了全面搜索,包括PubMed,科克伦图书馆,Embase,WebofScience,SinoMed,中国国家知识基础设施(CNKI),中国科技期刊数据库(VIP),和万方数据库。目的是确定随机对照试验(RCT),评估HBOT作为辅助治疗在缓解PD患者睡眠障碍症状方面的有效性。文献筛选和数据提取由作者独立执行。使用ReviewManager5.3软件进行Meta分析,使用Stata17.0软件评估发表偏倚和敏感性分析。
■纳入了7项RCT,涉及461名参与者。研究结果表明,HBOT的添加显着提高了睡眠效率(MD=15.26,95%CI[10.89,19.63],p<0.00001),卧床时间增加(MD=69.65,95%CI[43.01,96.30],p<0.00001),总睡眠时间(MD=75.87,95%CI[25.42,126.31],p=0.003),慢波睡眠(SWS)时间(MD=6.14,95%CI[3.95,8.34],p<0.00001),和快速眼动睡眠(REM)时间(MD=4.07,95%CI[2.05,6.08],p<0.0001),觉醒频率降低(MD=-11.55,95%CI[-15.42,-7.68],p<0.00001)和睡眠潜伏期(MD=-6.60,95%CI[-9.43,-3.89],p<0.00001)。此外,匹兹堡睡眠质量指数(PSQI)显着改善(MD=-2.52,95%CI[-2.85,-2.18],p<0.00001),Epworth嗜睡量表(ESS)(MD=-2.90,95%CI[-3.34,-2.47],p<0.00001),统一帕金森病评定量表第三部分(UPDRSIII)(MD=-1.32,95%CI[-2.16,-0.47],p=0.002),和Hoehn和Yahr分级(H-Y分级)(MD=-0.15,95%CI[-0.28,-0.01],p=0.03)。
■当前的荟萃分析支持HBOT作为治疗PD患者睡眠障碍的辅助疗法的有效性。建议用于经历睡眠障碍的PD患者。系统审查注册:https://www。crd.约克。AC.英国/,标识符:CRD42023462201。
UNASSIGNED: To systematically evaluate the efficacy of hyperbaric oxygen therapy (HBOT) as an adjunct therapy for treating sleep disorders in patients with Parkinson\'s disease (PD).
UNASSIGNED: We conducted comprehensive searches in eight databases from inception through September 2023, including PubMed, Cochrane Library, Embase, Web of Science, SinoMed,
China National Knowledge Infrastructure (CNKI),
China Science and Technology Periodical Database (VIP), and Wanfang Database. The objective was to identify randomized controlled trials (RCTs) evaluating HBOT\'s effectiveness in alleviating sleep disorder symptoms in PD patients as an adjunct therapy. Literature screening and data extraction were independently executed by the authors. Meta-analyses were performed using Review Manager 5.3 software, and publication bias and sensitivity analyses were assessed using Stata 17.0 software.
UNASSIGNED: Seven RCTs involving 461 participants were included. The findings revealed that the addition of HBOT significantly enhanced sleep efficiency (MD = 15.26, 95% CI [10.89, 19.63], p < 0.00001), increased time in bed (MD = 69.65, 95% CI [43.01, 96.30], p < 0.00001), total sleep time (MD = 75.87, 95% CI [25.42, 126.31], p = 0.003), slow-wave sleep (SWS) time (MD = 6.14, 95% CI [3.95, 8.34], p < 0.00001), and rapid eye movement sleep (REM) time (MD = 4.07, 95% CI [2.05, 6.08], p < 0.0001), and reduced awakening frequency (MD = -11.55, 95% CI [-15.42, -7.68], p < 0.00001) and sleep latency (MD = -6.60, 95% CI [-9.43, -3.89], p < 0.00001). Additionally, significant improvements were observed in the Pittsburgh Sleep Quality Index (PSQI) (MD = -2.52, 95% CI [-2.85, -2.18], p < 0.00001), Epworth Sleepiness Scale (ESS) (MD = -2.90, 95% CI [-3.34, -2.47], p < 0.00001), Unified Parkinson\'s Disease Rating Scale Part III (UPDRS III) (MD = -1.32, 95% CI [-2.16, -0.47], p = 0.002), and Hoehn and Yahr grading (H-Y grading) (MD = -0.15, 95% CI [-0.28, -0.01], p = 0.03).
UNASSIGNED: The current meta-analysis supports the efficacy of HBOT as an adjunct therapy in managing sleep disorders in PD patients. It is recommended for PD patients experiencing sleep disturbances.Systematic review registration:https://www.crd.york.ac.uk/, identifier: CRD42023462201.